Cabergoline for reducing the incidence of Ovarian Hyperstimulation Syndrome (OHSS) in women undergoing IVF/ICSI: a systematic review and meta-analysis of randomized controlled trials
Open Access
- 10 September 2026
- journal article
- review article
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 31 (1) , 72
Abstract
Background: Dopamine agonists are increasingly used to prevent ovarian hyperstimulation syndrome (OHSS), but the evidence remains fragmented. We synthesized comparative evidence on cabergoline for preventing moderate-to-severe OHSS in women undergoing IVF/ICSI, analysing randomized and non-randomized evidence as separate evidence streams. Methods: PubMed/MEDLINE, Embase, and the Cochrane Library were searched from inception to 1 May 2026. Randomized controlled trials (RCTs) and prospective non-randomized comparative studies comparing cabergoline with placebo or no treatment were eligible. Two reviewers independently performed selection, data extraction, and risk-of-bias assessment (RoB 2, ROBINS-I). In accordance with Cochrane guidance, randomized and non-randomized studies were not combined: the pooled estimate from the RCTs constituted the primary analysis, and the non-randomized studies were pooled separately as supportive evidence. Moderate-to-severe OHSS was expressed as an odds ratio (OR) using a random-effects model; certainty was rated with GRADE for each evidence stream. Results: Eight studies (969 women) were included: six RCTs (748 women) and two prospective non-randomized comparative studies (221 women). In the primary analysis restricted to the six RCTs, cabergoline was associated with a lower incidence of moderate-to-severe OHSS (OR 0.41, 95% CI 0.26–0.64; I² = 18%; 138 events). The two non-randomized studies, analysed separately, gave a consistent estimate (OR 0.21, 95% CI 0.07–0.66; I² = 0%). Assuming a baseline risk of 100 per 1,000 women, this corresponds to 57 fewer cases of moderate-to-severe OHSS per 1,000 women (95% CI 34 to 72 fewer). The estimate was robust in leave-one-out analysis (range OR 0.33–0.47) and after excluding the trial subject to an Expression of Concern (OR 0.42, 95% CI 0.25–0.73). No funnel-plot asymmetry was detected (Egger’s P = 0.90), but with six trials publication bias could not be reliably excluded. Clinical pregnancy, live birth, and adverse events were inconsistently reported and were not pooled. Certainty of evidence was Low for the randomized stream and Very low for the non-randomized stream. Conclusions: Low-certainty evidence indicates that cabergoline may reduce the incidence of moderate-to-severe OHSS in women undergoing IVF/ICSI. The available data did not identify a clear adverse signal for clinical pregnancy, live birth, or maternal adverse events, but were insufficient to determine these effects reliably. Cabergoline should be positioned as an adjunctive measure alongside, not instead of, contemporary primary prevention strategies.Keywords
This publication has 50 references indexed in Scilit:
- RETRACTION: Randomized Trial of Combined Cabergoline And Coasting in Preventing Ovarian Hyperstimulation Syndrome During in Vitro Fertilization/intracytoplasmic Sperm Injection CyclesInternational Journal of Gynecology & Obstetrics, 2026
- Expression of concern to “Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study” [EJOG 165(2) (2012) 254–258]European Journal of Obstetrics & Gynecology and Reproductive Biology, 2024
- Dopamine agonists for preventing ovarian hyperstimulation syndromeCochrane Database of Systematic Reviews, 2021
- Treating prolactinomas with dopamine agonists: always worth the gamble?Endocrine, 2015
- Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volumeReproductive Medicine and Biology, 2014
- Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled studyEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2012
- High dose cabergoline in management of ovarian hyperstimulation syndromeFertility and Sterility, 2009
- The economic impact of assisted reproductive technology: a review of selected developed countriesFertility and Sterility, 2009
- Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth CarrFertility and Sterility, 2005
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986